AR061618A1 - Formas de dosificacion unitaria de temozolomida - Google Patents

Formas de dosificacion unitaria de temozolomida

Info

Publication number
AR061618A1
AR061618A1 ARP070102775A ARP070102775A AR061618A1 AR 061618 A1 AR061618 A1 AR 061618A1 AR P070102775 A ARP070102775 A AR P070102775A AR P070102775 A ARP070102775 A AR P070102775A AR 061618 A1 AR061618 A1 AR 061618A1
Authority
AR
Argentina
Prior art keywords
dosage forms
unit dosage
temozolomide
refers
pills
Prior art date
Application number
ARP070102775A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR061618A1 publication Critical patent/AR061618A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ARP070102775A 2006-06-26 2007-06-22 Formas de dosificacion unitaria de temozolomida AR061618A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81662306P 2006-06-26 2006-06-26

Publications (1)

Publication Number Publication Date
AR061618A1 true AR061618A1 (es) 2008-09-10

Family

ID=38704663

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102775A AR061618A1 (es) 2006-06-26 2007-06-22 Formas de dosificacion unitaria de temozolomida

Country Status (13)

Country Link
EP (1) EP1901740A2 (no)
JP (1) JP2008534692A (no)
KR (2) KR20100055543A (no)
CN (1) CN101309686A (no)
AR (1) AR061618A1 (no)
AU (1) AU2007221979A1 (no)
BR (1) BRPI0702847A (no)
CA (1) CA2610439A1 (no)
CL (1) CL2007001864A1 (no)
NO (1) NO20074913L (no)
TW (1) TWI326598B (no)
WO (1) WO2008002544A2 (no)
ZA (1) ZA200708280B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526038B (zh) * 2011-01-12 2013-09-11 北京人福军威医药技术开发有限公司 替莫唑胺的脑靶向药物组合物及其应用
US10744171B2 (en) * 2016-03-21 2020-08-18 Duke University Sequential anti-cancer treatment
US11147810B2 (en) 2017-03-13 2021-10-19 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of anti-neoplastic alkylating agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251987T3 (es) * 1999-03-30 2006-05-16 Schering Corporation Tratamiento mejorado del cancer con temozolomida.
US20060100188A1 (en) * 2004-11-09 2006-05-11 Chen Zong Treatment methods

Also Published As

Publication number Publication date
WO2008002544A2 (en) 2008-01-03
WO2008002544A3 (en) 2008-02-07
KR20080015777A (ko) 2008-02-20
JP2008534692A (ja) 2008-08-28
BRPI0702847A (pt) 2008-04-01
CN101309686A (zh) 2008-11-19
ZA200708280B (en) 2009-03-25
EP1901740A2 (en) 2008-03-26
AU2007221979A9 (en) 2008-01-10
KR20100055543A (ko) 2010-05-26
AU2007221979A1 (en) 2008-01-10
NO20074913L (no) 2009-03-26
TWI326598B (en) 2010-07-01
CA2610439A1 (en) 2007-12-26
TW200808803A (en) 2008-02-16
CL2007001864A1 (es) 2008-02-08

Similar Documents

Publication Publication Date Title
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
EA201100335A1 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
AR059390A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
CL2013002869A1 (es) Una combinacion que contiene 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida y abt-737; y su uso para el tratamiento o profilaxis de cancer de mama, en particular cáncer de mama inflamatorio, cancer de mama triple negativo, cancer de mama positivo a receptor de her2 y cancer de mama positivo a receptor de hormona.
CO7200273A2 (es) Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
CL2009001099A1 (es) Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune.
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
BRPI0914678A8 (pt) Dispositivo dispensador para vaso sanitário e processo para distribuir uma composição de tratamento a um dispositivo sanitário
ECSP12011962A (es) Tratamientos para trastornos gastrointestinales
UY31136A1 (es) Oxazolidinonas sustituidas y su uso
UY29777A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
DOP2009000207A (es) Nueva forma de dosificación
CL2014000606A1 (es) Combinacion farmaceutica que comprende al compuesto 2-{2-[(2s)-2-metil-2,3-dihidro-1h-indol-1-il]-2-oxoetil}-6-(morfolin-4-il)pirimidin-4-(3h)-ona y al menos un inhibidor de la via de mapk; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento del cancer.
CL2009000322A1 (es) Composicion farmaceutica que comprende flibanserina en su forma amorfa y al menos un excipiente, sistema farmaceutico de liberacion que comprende esta composicion, metodo para fabricar este sistema y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, trastornos del sueño y sexuales, entre otros.
ECSP12012132A (es) Combinación de teobromina con un descongestivo y su uso para el tratamiento de la tos
PA8824601A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
AR061618A1 (es) Formas de dosificacion unitaria de temozolomida

Legal Events

Date Code Title Description
FB Suspension of granting procedure